Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects
Identifieur interne : 003420 ( Main/Exploration ); précédent : 003419; suivant : 003421Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects
Auteurs : Katie Kompoliti [États-Unis] ; Christopher G. Goetz [États-Unis] ; Mary Morrissey [États-Unis] ; Sue Leurgans [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-02.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adolescent, Adult, Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Awareness, Brain (drug effects), Child, Child, Preschool, Cohort Studies, Comorbidity, Dopamine, Dyskinesia, Gilles de la Tourette syndrome, Health Knowledge, Attitudes, Practice, Human, Humans, Nervous system diseases, Neuroleptic, Patient Education as Topic, Questionnaires, Tic, Tourette Syndrome (diagnosis), Toxicity, dopamine blockers, neuroleptics, tardive dyskinesia, tics, toxicity.
- MESH :
- chemical , adverse effects : Antipsychotic Agents.
- chemical , therapeutic use : Antipsychotic Agents.
- diagnosis : Tourette Syndrome.
- drug effects : Brain.
- Adolescent, Adult, Awareness, Child, Child, Preschool, Cohort Studies, Comorbidity, Health Knowledge, Attitudes, Practice, Humans, Patient Education as Topic, Questionnaires.
Abstract
The objective of this study was to assess awareness and concern of neuroleptic (NL)‐induced side effects in Gilles de la Tourette syndrome (GTS) patients. Although NLs are effective tic suppressants, they can be associated with various side effects. Data on patient knowledge and concern about side effects can guide educational efforts. One hundred consecutive GTS patients or parents in a tertiary referral medical center responded to a standardized, in‐person questionnaire. They were given a list of 15 side effects and asked which could be ascribed to NLs (9) or not (6). Side effect concern was rated on a 0 (none) to 10 (extreme) scale. The mean age for the 100 patients was 19.4 ± 14 years; 55 had a history of NL use, and 45 were NL‐naive. Less than half the cohort met criteria for being well informed. Only one third of the listed NL side effects were accurately identified by at least 75% of the respondents. Patients with past or current NL treatment were more accurate in identifying NL side effects but less concerned about them than NL‐naive patients. The side effects of greatest concern were seizures, tardive dyskinesia, thinking and emotion disturbances, and cardiac irregularities. Overall, patient awareness of NL side effects is insufficient, and although past exposure to NLs enhances knowledge, it decreases concern. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20680
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001C04
- to stream Istex, to step Curation: 001C04
- to stream Istex, to step Checkpoint: 001E80
- to stream PubMed, to step Corpus: 002E77
- to stream PubMed, to step Curation: 002E77
- to stream PubMed, to step Checkpoint: 002D11
- to stream Ncbi, to step Merge: 001435
- to stream Ncbi, to step Curation: 001435
- to stream Ncbi, to step Checkpoint: 001435
- to stream Main, to step Merge: 004734
- to stream PascalFrancis, to step Corpus: 001C52
- to stream PascalFrancis, to step Curation: 001069
- to stream PascalFrancis, to step Checkpoint: 001A84
- to stream Main, to step Merge: 004B79
- to stream Main, to step Curation: 003420
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects</title><author><name sortKey="Kompoliti, Katie" sort="Kompoliti, Katie" uniqKey="Kompoliti K" first="Katie" last="Kompoliti">Katie Kompoliti</name></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name></author><author><name sortKey="Morrissey, Mary" sort="Morrissey, Mary" uniqKey="Morrissey M" first="Mary" last="Morrissey">Mary Morrissey</name></author><author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2D255853C3BEEE64669F67CBCF5C55BC26EA5770</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20680</idno><idno type="url">https://api.istex.fr/document/2D255853C3BEEE64669F67CBCF5C55BC26EA5770/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C04</idno><idno type="wicri:Area/Istex/Curation">001C04</idno><idno type="wicri:Area/Istex/Checkpoint">001E80</idno><idno type="wicri:doubleKey">0885-3185:2006:Kompoliti K:gilles:de:la</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16161137</idno><idno type="wicri:Area/PubMed/Corpus">002E77</idno><idno type="wicri:Area/PubMed/Curation">002E77</idno><idno type="wicri:Area/PubMed/Checkpoint">002D11</idno><idno type="wicri:Area/Ncbi/Merge">001435</idno><idno type="wicri:Area/Ncbi/Curation">001435</idno><idno type="wicri:Area/Ncbi/Checkpoint">001435</idno><idno type="wicri:doubleKey">0885-3185:2006:Kompoliti K:gilles:de:la</idno><idno type="wicri:Area/Main/Merge">004734</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0171953</idno><idno type="wicri:Area/PascalFrancis/Corpus">001C52</idno><idno type="wicri:Area/PascalFrancis/Curation">001069</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001A84</idno><idno type="wicri:doubleKey">0885-3185:2006:Kompoliti K:gilles:de:la</idno><idno type="wicri:Area/Main/Merge">004B79</idno><idno type="wicri:Area/Main/Curation">003420</idno><idno type="wicri:Area/Main/Exploration">003420</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects</title><author><name sortKey="Kompoliti, Katie" sort="Kompoliti, Katie" uniqKey="Kompoliti K" first="Katie" last="Kompoliti">Katie Kompoliti</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Morrissey, Mary" sort="Morrissey, Mary" uniqKey="Morrissey M" first="Mary" last="Morrissey">Mary Morrissey</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-02">2006-02</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="248">248</biblScope><biblScope unit="page" to="252">252</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2D255853C3BEEE64669F67CBCF5C55BC26EA5770</idno><idno type="DOI">10.1002/mds.20680</idno><idno type="ArticleID">MDS20680</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Antipsychotic Agents (adverse effects)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Awareness</term><term>Brain (drug effects)</term><term>Child</term><term>Child, Preschool</term><term>Cohort Studies</term><term>Comorbidity</term><term>Dopamine</term><term>Dyskinesia</term><term>Gilles de la Tourette syndrome</term><term>Health Knowledge, Attitudes, Practice</term><term>Human</term><term>Humans</term><term>Nervous system diseases</term><term>Neuroleptic</term><term>Patient Education as Topic</term><term>Questionnaires</term><term>Tic</term><term>Tourette Syndrome (diagnosis)</term><term>Toxicity</term><term>dopamine blockers</term><term>neuroleptics</term><term>tardive dyskinesia</term><term>tics</term><term>toxicity</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Tourette Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Awareness</term><term>Child</term><term>Child, Preschool</term><term>Cohort Studies</term><term>Comorbidity</term><term>Health Knowledge, Attitudes, Practice</term><term>Humans</term><term>Patient Education as Topic</term><term>Questionnaires</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dopamine</term><term>Dyskinésie</term><term>Gilles de la Tourette syndrome</term><term>Homme</term><term>Neuroleptique</term><term>Système nerveux pathologie</term><term>Tic</term><term>Toxicité</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to assess awareness and concern of neuroleptic (NL)‐induced side effects in Gilles de la Tourette syndrome (GTS) patients. Although NLs are effective tic suppressants, they can be associated with various side effects. Data on patient knowledge and concern about side effects can guide educational efforts. One hundred consecutive GTS patients or parents in a tertiary referral medical center responded to a standardized, in‐person questionnaire. They were given a list of 15 side effects and asked which could be ascribed to NLs (9) or not (6). Side effect concern was rated on a 0 (none) to 10 (extreme) scale. The mean age for the 100 patients was 19.4 ± 14 years; 55 had a history of NL use, and 45 were NL‐naive. Less than half the cohort met criteria for being well informed. Only one third of the listed NL side effects were accurately identified by at least 75% of the respondents. Patients with past or current NL treatment were more accurate in identifying NL side effects but less concerned about them than NL‐naive patients. The side effects of greatest concern were seizures, tardive dyskinesia, thinking and emotion disturbances, and cardiac irregularities. Overall, patient awareness of NL side effects is insufficient, and although past exposure to NLs enhances knowledge, it decreases concern. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li></region></list><tree><country name="États-Unis"><region name="Illinois"><name sortKey="Kompoliti, Katie" sort="Kompoliti, Katie" uniqKey="Kompoliti K" first="Katie" last="Kompoliti">Katie Kompoliti</name></region><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name><name sortKey="Morrissey, Mary" sort="Morrissey, Mary" uniqKey="Morrissey M" first="Mary" last="Morrissey">Mary Morrissey</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003420 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003420 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2D255853C3BEEE64669F67CBCF5C55BC26EA5770
|texte= Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects
}}
| This area was generated with Dilib version V0.6.23. |  |